Wright Medical Group, Inc. Highlights New Innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) Annual Meeting

  Wright Medical Group, Inc. Highlights New Innovations at the American
  Orthopaedic Foot and Ankle Society (AOFAS) Annual Meeting 2013

    Announces U.S. Commercial Launch of ORTHOLOC^® 3Di Ankle Fusion System

Business Wire

ARLINGTON, Tenn. -- July 17, 2013

Wright Medical Group, Inc. (NASDAQ: WMGI) today announced the U.S. commercial
launch of the ORTHOLOC^® 3Di Ankle Fusion System at the American Orthopaedic
Foot and Ankle Society (AOFAS) Annual Meeting 2013 taking place at the Westin
Diplomat in Hollywood, Florida from July 17-20, 2013.

Offering six unique plate designs and five screw options, the ORTHOLOC^® 3Di
Ankle Fusion System offers implant options for a lateral, anterior, or
posterior surgical approach. These options, combined with Wright’s innovative
3Di Polyaxial Locking Technology, provide a versatile and comprehensive
fixation solution, enabling the surgeon to create an ankle fusion plating
construct specific to the unique needs of the patient. The ORTHOLOC^® 3Di
Ankle Fusion System further expands Wright’s product portfolio to address the
various complexities associated with treating ankle arthritis.

In addition to the ORTHOLOC^® 3Di Ankle Fusion System, Wright will also be
exhibiting several new line extensions related to the ORTHOLOC^® 3Di Foot
Reconstruction System, as well as featuring the innovative PROPHECY^® INBONE^®
Total Ankle System at exhibit booth #103 at the AOFAS annual meeting. Wright
will also be sponsoring several medical education and training events during
the annual meeting with its mobile training lab located onsite.

More information on Wright Medical’s foot and ankle products, including the
ORTHOLOC^® 3Di Ankle Fusion System, can be found at

About Wright Medical

Wright Medical Group, Inc. is a global orthopaedic company that provides
solutions that enable clinicians to alleviate pain and restore their patients’
lifestyles. The company is the recognized leader of surgical solutions for the
foot and ankle market and markets its products in over 60 countries worldwide.
For more information about Wright Medical, visit www.wmt.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” as defined under
U.S. federal securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and express
management's current view of future performance, results, and trends. Forward-
looking statements may be identified by their use of terms such as anticipate,
believe, could, estimate, expect, intend, may, plan, predict, project, will,
and other similar terms. Forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results to materially differ
from those described in the forward-looking statements. The reader should not
place undue reliance on forward-looking statements. Such statements are made
as of the date of this press release, and we undertake no obligation to update
such statements after this date. Risks and uncertainties that could cause our
actual results to materially differ from those described in forward-looking
statements are discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on Form
10-K for the year ended December 31, 2012, and as may be supplemented in our
Quarterly Reports on Form 10-Q). By way of example and without implied
limitation, such risks and uncertainties include: failure to realize the
anticipated financial and other benefits from the acquisition of BioMimetic
Therapeutics, Inc. or a delay in realization thereof; failure to obtain, or a
delay in obtaining, FDA approval of Augment Bone Graft, or a material
limitation on the scope of such approval; lower than anticipated market
acceptance of, or annual market demand for, Augment Bone Graft; failure to
obtain necessary approvals, or other intervening events, which could delay or
prevent the previously announced sale of our hip/knee business from closing;
future actions of the United States Attorney's office, the FDA, the Department
of Health and Human Services or other U.S. or foreign government authorities,
including those resulting from increased scrutiny under the Foreign Corrupt
Practices Act and similar laws, that could delay, limit or suspend our
development, manufacturing, commercialization and sale of products, or result
in seizures, injunctions, monetary sanctions or criminal or civil liabilities;
failure to obtain the FDA or other regulatory clearances needed to market and
sell our products; any actual or alleged breach of the Corporate Integrity
Agreement to which we are subject through September 2015 which could expose us
to significant liability including exclusion from Medicare, Medicaid and other
federal healthcare programs, potential criminal prosecution, and civil and
criminal fines or penalties; adverse outcomes in existing product liability
litigation; new product liability claims; inadequate insurance coverage; the
possibility of private securities litigation or shareholder derivative suits;
demand for and market acceptance of our new and existing products; potentially
burdensome tax measures; recently enacted healthcare laws and changes in
product reimbursement which could generate downward pressure on our product
pricing; lack of suitable business development opportunities; inability to
capitalize on business development opportunities; product quality or patient
safety issues; challenges to our intellectual property rights; geographic and
product mix impact on our sales; our inability to retain key sales
representatives, independent distributors and other personnel or to attract
new talent; inventory reductions or fluctuations in buying patterns by
wholesalers or distributors; inability to realize the anticipated benefits of
restructuring initiatives; negative impact of the commercial and credit
environment on us, our customers and our suppliers; and the potentially
negative effect of our ongoing compliance enhancements on our relationships
with customers and our ability to deliver timely and effective medical
education, clinical studies, and new products.


Wright Medical Group, Inc.
Julie D. Tracy, 901-290-5817
Sr. Vice President, Chief Communications Officer
Press spacebar to pause and continue. Press esc to stop.